Abstract
All eyes are on the nucleoside analogues famciclovir and lamivudine regarding their potential as treatments for hepatitis B infection. At present, interferon-α is the only agent approved for this indication. Clinical trials have indicated that interferon-α is only effective in some 40% of patients infected with hepatitis B virus (HBV); thus, new therapies are urgently required. Currently, both lamivudine and famciclovir are in clinical trials for hepatitis B infection. An update of progress in this field of research was presented during a SmithKline Beecham-sponsored symposium at the International Conference on Infectious Disease [ Hong Kong; June 1996 ].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
